Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a

International Journal of Molecular Medicine

Volumn 36, Issue 4, 2015, Pages 957-966

  Zhang, Lirui ^a   Yang, Xiaofeng ^a   Li, Xu ^a   Li, Chen ^a   Zhao, Le ^a   Zhou, Yuanyuan ^a   Hou, Huilian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Butein; Cisplatin; Extracellular signal regulated kinases; Forkhead box O3; P38 kinases; Protein kinase B

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BUTEIN; CISPLATIN; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P27; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; CHALCONE DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL POPULATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SENSITIZATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

ANIMALS; CHALCONES; CISPLATIN; FEMALE; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; HELA CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; UTERINE CERVICAL NEOPLASMS;

EID: 84940368287     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2324     Document Type: Article

References (48)

1. Basu A and Krishnamurthy S: Cellular responses to cisplatin-induced DNA damage. J Nuleic Acids 2010: Article ID 201367, 2010.
2. Brozovic A and Osmak M: Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1-16, 2007.
3. Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W, Meng J, Wang Y, Sun H, Gu H, et al: Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways. PLoS One 8: e79117, 2013.
4. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005.
5. Kang DG, Lee AS, Mun YJ, Woo WH, Kim YC, Sohn EJ, Moon MK and Lee HS: Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biol Pharm Bull 27: 366-370, 2004.
6. Wang Y, Chan FL, Chen S and Leung LK: The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase. Life Sci 77: 39-51, 2005.
7. Cho SG, Woo SM and Ko SG: Butein suppresses breast cancer growth by reducing a production of intracellular reactive oxygen species. J Exp Clin Cancer Res 33: 51, 2014.
8. Yit CC and Das NP: Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Cancer Lett 82: 65-72, 1994.
9. Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY, Yu CC and Chung JG: Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways. J Agric Food Chem 59: 9032-9038, 2011.
10. Zhang L, Chen W and Li X: A novel anticancer effect of butein: Inhibition of invasion through the ERK1/2 and NF-kappa B signaling pathways in bladder cancer cells. FEBS Lett 582: 1821-1828, 2008.
11. Lau GT, Huang H, Lin SM and Leung LK: Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells. Eur J Pharmacol 648: 24-30, 2010.
12. Khan N, Adhami VM, Afaq F and Mukhtar H: Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal 16: 1195-1204, 2012.
13. Jin ZJ: About the evaluation of drug combination. Acta Pharmacol Sin 25: 146-147, 2004.
14. Moon DO, Kim MO, Choi YH, Hyun JW, Chang WY and Kim GY: Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. Cancer Lett 288: 204-213, 2010.
15. Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N and Naito S: Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101: 1177-1185, 2010.
16. Khatri S, Yepiskoposyan H, Gallo CA, Tandon P and Plas DR: FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol Chem 285: 15960-15965, 2010.
17. Yang W, Dolloff NG and El-Deiry WS: ERK and MDM2 prey on FOXO3a. Nat Cell Biol 10: 125-126, 2008.
18. Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M, Palermo R, Murzilli S, Campese AF, Ingravallo G, et al: Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38? modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett 344: 110-118, 2014.
19. Quast SA, Berger A, Plötz M and Eberle J: Sensitization of melanoma cells for TRAIL-induced apoptosis by activation of mitochondrialpathways via Bax. Eur J Cell Biol 93: 42-48, 2014.
20. Kim MJ, Yun HS, Hong EH, Lee SJ, Baek JH, Lee CW, Yim JH, Kim JS, Park JK, Um HD and Hwang SG: Depletion of end-binding protein 1 (EB1) promotes apoptosis of human non-small-cell lung cancer cells via reactive oxygen species and Bax-mediated mitochondrial dysfunction. Cancer Lett 339: 15-24, 2013.
21. Hsu HH, Cheng LH, Ho TJ, Kuo WW, Lin YM, Chen MC, Lee NH, Tsai FJ, Tsai KH and Huang CY: Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation. Tumour Biol 35: 303-313, 2014.
22. Persons DL, Yazlovitskaya EM, Cui W and Pelling JC: Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5: 1007-1014, 1999.
23. Wang J, Zhou JY and Wu GS: Bim protein degradation contributes to cisplatin resistance. J Biol Chem 286: 22384-22392, 2011.
24. Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435-39443, 2000.
25. Wang X, Govind S, Sajankila SP, Mi L, Roy R and Chung FL: Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin. Mol Nutr Food Res 55: 1572-1581, 2011.
26. Sheridan C, Brumatti G, Elgendy M, Brunet M and Martin SJ: An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 29: 6428-6441, 2010.
27. Guégan JP, Ezan F, Théret N, Langouët S and Baffet G: MAPK signaling in cisplatin-induced death: Predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells. Carcinogenesis 34: 38-47, 2013.
28. Wang Y, Lin B, Wu J, Zhang H and Wu B: Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase. Oncol Lett 8: 1269-1274, 2014.
29. Pereira L, Igea A, Canovas B, Dolado I and Nebreda AR: Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med 5: 1759-1774, 2013.
30. Feng R, Zhai WL, Yang HY, Jin H and Zhang QX: Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK. Biochem Biophys Res Commun 406: 299-304, 2011.
31. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN and Bacus SS: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100: 499-506, 2004.
32. Wang SN, Lee KT, Tsai CJ, Chen YJ and Yeh YT: Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest 42: 1295-1301, 2012.
33. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A and Nebreda AR: p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11: 191-205, 2007.
34. Voisset E, Oeztuerk-Winder F, Ruiz EJ and Ventura JJ: p38? negatively regulates survival and malignant selection of transformed bronchioalveolar stem cells. PLoS One 8: e78911, 2013.
35. Piaggi S, Raggi C, Corti A, Pitzalis E, Mascherpa MC, Saviozzi M, Pompella A and Casini AF: Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis 31: 804-811, 2010.
36. Ishitsuka A, Fujine E, Mizutani Y, Tawada C, Kanoh H, Banno Y and Seishima M: FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression. Int J Mol Med 34: 1169-1174, 2014.
37. Berra E, Diaz-Meco MT and Moscat J: The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol Chem 273: 10792-10797, 1998.
38. Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, Russo S, Moyer MP, Resta N, Murzilli S, et al: Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett 324: 98-108, 2012.
39. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237, 2004.
40. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148, 2008.
41. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A and Simone C: p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha-to FoxO-dependent transcription. Cell Death Differ 16: 1203-1214, 2009.
42. Chiacchiera F and Simone C: Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 5: 1030-1033, 2009.
43. Zhang X, Tang N, Hadden TJ and Rishi AK: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813: 1978-1986, 2011.
44. Ho KK, Myatt SS and Lam EW: Many forks in the path: Cycling with FoxO. Oncogene 27: 2300-2311, 2008.
45. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM and Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842-7852, 2002.
46. Massagué J: G1 cell-cycle control and cancer. Nature 432: 298-306, 2004.
47. Lee MT, Ho SM, Tarapore P, Chung I and Leung YK: Estrogen receptor ? isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12. Neoplasia 15: 1262-1271, 2013.
48. Kiyoshima T1, Yoshida H, Wada H, Nagata K, Fujiwara H, Kihara M, Hasegawa K, Someya H and Sakai H: Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS One 8: e80998, 2013.